Clinical Trials Logo

Blepharitis clinical trials

View clinical trials related to Blepharitis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06054217 Active, not recruiting - Clinical trials for Meibomian Gland Dysfunction

Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

Rhea
Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate and compare the effect of two dosing regimens, BID versus TID dosing, of an Exploratory Vehicle (EV) on meibomian gland dysfunction (MGD) in patients with Demodex lid infestation.

NCT ID: NCT05629390 Active, not recruiting - Blepharitis Clinical Trials

Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study

Start date: October 23, 2022
Phase: Phase 3
Study type: Interventional

The Phase III main study is a randomized, controlled, multicenter, double blind, trial to evaluate the efficacy and safety of TP-03 (lotilaner ophthalmic solution, 0.25%), for the treatment of Demodex blepharitis in Chinese patients. The PK sub-study is a single-arm, open-label trial to evaluate systemic TP-03 in whole blood following topical ocular administration

NCT ID: NCT01456780 Active, not recruiting - Clinical trials for Meibomian Gland Dysfunction

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

ZvL
Start date: August 2011
Phase: Phase 4
Study type: Interventional

This is a Phase IV, single site, randomized, double masked, parallel control clinical trial of 60 subjects to investigate the variance of efficacy between Lotemax® and Zylet® for treatment of ocular surface inflammation due to meibomian gland dysfunction (MGD). Efficacy will be measured by in-vivo confocal microscopy, corneal fluorescein staining, grading of meibomian gland dysfunction and validated ocular symptom assessment questionnaire.